Full Press Release Details
Launches Social Media Pages to Enhance Investor and Trade Relationships
Mass., September 11, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate"
or the "Company"), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products
using two proprietary platform technologies for treating diseases and disorders of the eye, today announced its launch of a social
media presence on Facebook, Twitter and LinkedIn.
information distributed through the social media channels may be deemed material, investors should follow or like the following
pages in addition to monitoring EyeGate's website, press releases, SEC filings and other traditional channels.
https://twitter.com/EyeGatePharma (@EyeGatePharma)
media is an increasingly effective way to enhance relationships within the investor and medical research communities," commented
Stephen From, EyeGate's President and CEO. "Investors, development partners, employees, vendors and all EyeGate stakeholders
will benefit from greater insight into our business that results from our posts on these pages".
a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using its two proprietary
platform technologies for treating diseases and disorders of the eye. EyeGate's most advanced platform is based on a cross-linked
thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid ("HA"),
which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular
surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes
it well-suited for treating various ocular surface injuries.
other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is
delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery
System. For more information, please visit www.EyeGatePharma.com.
its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter
account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels
of distribution of information about EyeGate and its product candidates. Such information may be deemed material information,
and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should
monitor EyeGate's website and its social media accounts in addition to following its press releases, SEC filings, public
conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information
described above may be updated from time to time as listed on EyeGate's investor relations website.
Forward-looking Statements
Some of the statements in this press release
are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform
Act of 1995. These "forward-looking" statements include statements relating to, among other things, the commercialization
efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EyeGate's EGP-437
combination product and those of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate, as well as the success thereof,
with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and
uncertainties that may cause results to differ materially from the statements set forth in this press release, plus other risk
factors described under the heading "Risk Factors" contained in EyeGate's Annual Report on Form 10-K filed with
the SEC on February 23, 2017 or described in EyeGate's other public filings. EyeGate's results may also be affected
by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date
of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to
such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances
on which any such statement is based.
for EyeGate Pharmaceuticals